MOTS-c side effects: what is known, what is unknown, and what to watch for

The honest answer about the side effects of MOTS-c is that they are unknown. No human trial of MOTS-c has published safety data, so there is no list of common or rare side effects with percentages, the way there is for an approved drug. What exists is one small study of a modified version called CB4211, FDA’s 2026 safety review, some mouse data, and the general risks of injecting any unregulated product. MOTS-c is not FDA-approved, so no label lists its risks.

What has been reported, by source

CB4211 is not the MOTS-c sold online. CohBar described it as a modified analogue, and it was given in a formulation that CohBar itself had to change. Its safety record is the nearest clue available, not a substitute for data on MOTS-c.

When do side effects start, and do they fade?

For MOTS-c, no one has measured this. The only timing clue comes from CB4211, where events were described as transient, yet the earlier phase was paused because some site reactions were “unexpectedly persistent” and lasted longer than the company expected. The trial ran for 4 weeks, so it says nothing about months of use, including any immune response to the peptide. MOTS-MET lists anti-drug antibodies as an outcome, and has not reported.

What FDA flagged

FDA’s July 2026 briefing document is the most detailed public safety review of MOTS-c. Its main points:

• Immunogenicity. FDA is “concerned about potential for immunogenicity when administered by an injection” route, meaning the body could make antibodies against the peptide. FDA ties this to aggregation (peptide molecules clumping together) and to peptide-related impurities, and says there are “insufficient data to conclude that MOTS-c-related BDSs do not present these risks.”
• No toxicology package. FDA found no nonclinical developmental and reproductive studies of MOTS-c and no carcinogenicity studies, and concluded there are “no available nonclinical data to inform safety considerations” for the uses it reviewed.
• Uncharacterized products. FDA noted there was no certificate of analysis for the free base in the nomination, that certificates for the acetate form showed purity but no impurity profile, and that different salts and derivatives are sold under the same name.
• No human exposure data. FDA’s safety-risk page says it “has not identified any human exposure data on drug products containing MOTs-C” by any route.

FDA’s reviewers proposed against adding MOTS-c to the compounding bulks list. The advisory committee voted to recommend it anyway on July 23, 2026. That vote did not produce any new safety information.

Does the October 2026 HHS policy mean MOTS-c is safe?

No. As of November 2, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding MOTS-c acetate for subcutaneous or intramuscular injection, if ten conditions are met, until a final rule addresses it. That is a choice not to enforce. MOTS-c remains unapproved and off the 503A bulks list, no rule has been proposed, and FDA has reviewed no compounded product for safety, effectiveness or quality.

HHS’s document says “the available safety evidence points in one direction”, citing the CB4211 trial and rodent studies. Read that against what those sources are: a 4-week study of a different molecule, and mouse papers that did not set out to measure harm. FDA’s reviewers looked at the same field and called the human risks unknown. Some conditions in the policy do help on the product side, such as lot testing for endotoxin and impurities, and mandatory reporting of serious adverse events to FDA MedWatch. Those reduce some of the risks described below for vials that meet them. They do not tell you what the peptide itself does.

The notice says the policy is not binding, comments run until November 13, 2026, HHS may revisit it if a safety signal or quality problem appears, it covers 503A compounding only, and states can be stricter.

What the mouse studies suggest

The mouse papers were designed to measure benefits, not harms, and they do not report a systematic safety assessment. Two observations matter for safety:

• Blood sugar falls. In the 2015 study, short-term treatment in mice on a normal diet modestly reduced blood glucose, body weight and food intake. In people taking insulin or other glucose-lowering drugs, that raises a theoretical risk of low blood sugar that no study has measured.
• Animal results do not predict human side effects reliably. The mice received injections into the abdominal cavity, a route not used in people, and most experiments lasted days to weeks.

The general risks of unregulated injectables

These apply to any vial sold outside the drug approval system, and they are often bigger than the risks of the molecule itself. A 2026 Sports Medicine review of unapproved peptides concluded that rigorous human safety data are scarce and that there is potential for serious harm.

• Unknown contents. Research-grade vials have no FDA-verified identity, strength or purity. The label may not match what is inside.
• Sterility and endotoxins. Injected products need sterility testing and bacterial endotoxin testing. FDA describes these as “critical safety factors” for injections, and the MOTS-c certificate of analysis reproduced in its briefing listed purity and composition results but no sterility or endotoxin results. A contaminated vial can cause abscesses or a bloodstream infection.
• Mixing and storage errors. Powdered peptide must be mixed with sterile water and kept cold. Mistakes in mixing change the dose; see how to reconstitute and the MOTS-c dosage chart.
• No accountability. There is no manufacturer obliged to investigate or report a problem, and no recall system.

The arithmetic is covered by the reconstitution calculator, and our overview of peptide safety explains how these risks differ across approved, compounded and research products.

What helps with side effects?

No treatment or tip has been tested for MOTS-c side effects, so we will not offer a list that sounds more certain than it is. CohBar’s response to persistent lumps was to change the formulation, which is a manufacturing fix and not something a patient can do. If a site stays lumpy, sore or red, the useful step is to stop and have it looked at. Someone taking a prescribed compounded product should tell the prescriber and the pharmacy, since compounders working under the HHS policy must report serious events.

Who should be especially cautious

• People with diabetes or on glucose-lowering drugs, because of the blood sugar effect seen in mice and the absence of any interaction data. The MOTS-MET trial excludes people with diabetes and anyone who used glucose-lowering medicines in the prior 3 months.
• Anyone pregnant, trying to conceive or breastfeeding, because no reproductive or developmental studies exist. MOTS-MET excludes this group too.
• People with a history of allergic reactions to injected drugs, given FDA’s immunogenicity concern. MOTS-MET excludes known hypersensitivity to peptide therapeutics.
• Competitive athletes, because WADA lists MOTS-c under class S4, prohibited at all times.

Red flags and when to get help

Signs that call for prompt medical care after any injection:

• Spreading redness, warmth or pus at the site
• Fever
• Hives
• Swelling of the face or throat, or trouble breathing

Trouble breathing or throat swelling is an emergency, so call 911. Anyone who has a reaction can report it to FDA’s MedWatch program, which is how FDA learns about problems with unapproved products. Tell any clinician treating you exactly what you injected and bring the vial if you still have it.

The legal line for research products

Products labeled “for research use only” are not legal to use on people. The label comes from 21 CFR 312.160, under which a product may be shipped only for laboratory animal or test-tube work, marked “Not for use in humans.” FDA warning letters, including one in March 2026, have said that disclaimer does not protect a seller whose marketing targets people, and the HHS policy gives such products nothing. The FDA status tracker follows the rulemaking.